Abstracts Archive - Page 478 of 1683 - ATC Abstracts

2020 American Transplant Congress
Granulocyte Colony Stimulating Factor: Trigger of Rejection in Lung Transplantation?
K. Walter¹, M. Patti¹, S. Khalid², L. Kemp¹, L. J. Lobo³, R. Coakley³, S. Krishnan³, C. T. Doligalski¹
¹University of North Carolina Medical Center, Chapel Hill, NC, ²Eshelman School of Pharmacy, Chapel Hill, NC, ³Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
*Purpose: Granulocyte colony stimulating factor (GCSF) is a management strategy for post-transplant neutropenia, but may increase the risk of rejection in lung transplant recipients (LTRs).…
2020 American Transplant Congress
Alternate Triazole Therapy for Breakthrough Invasive Fungal Disease in Lung Transplant Recipients on Triazole Prophylaxis
A. Abbas, H. Hassouna, F. Marco Canosa, K. D. Brizendine
Cleveland Clinic Foundation, Cleveland, OH
*Purpose: Invasive fungal diseases (IFD) are a leading cause of infection related morbidity and mortality in lung transplant (LT) recipients. Data regarding outcomes of breakthrough…
2020 American Transplant Congress
Impact of the 2015 LAS Revisions on Lung Candidates with Pulmonary Vascular Disease
K. Lindblad¹, R. Goff¹, K. Chan²
¹UNOS, Richmond, VA, ²University of Michigan, Ann Arbor, MI
*Purpose: On February 19, 2015 a major revision to the Lung Allocation Score (LAS) was implemented with the goal of more accurately reflecting waitlist urgency…
2020 American Transplant Congress
Is Total Ischemic Time a Measure of OPTN Efficiency? Monitoring the Impact of Lung Allocation Policy on Ischemic Time
A. M. Placona¹, R. R. Goff¹, P. Shay², B. Carrico¹
¹United Network for Organ Sharing, Richmond, VA, ²Health Administration, Trinity University, San Antonio, TX
*Purpose: There is concern that the shift to circle based organ allocation policy may increase coordination costs. Within both public comment and the peer reviewed…
2020 American Transplant Congress
Outpatient Treatment of Paramyxovirus with Oral Ribavirin is Safe and Effective in Lung Transplant Recipients
A. W. Rogers¹, B. J. Pierce¹, C. Pham¹, J. T. Swan¹, H. J. Huang²
¹Department of Pharmacy, Houston Methodist Hospital, Houston, TX, ²Department of Medicine, Houston Methodist Hospital, Houston, TX
*Purpose: Respiratory paramyxovirus infections present an increased risk to lung transplant recipients (LTRs), including rapid decline in graft function and immunologic sequelae such as rejection…
2020 American Transplant Congress
Alterations in Left Ventricular Wall Thickness after Cardiac Transplantation
C. K. Alvarez, O. Saeed, S. R. Patel, E. Borukhov, U. Jorde
Advanced Heart Failure, Transplant and Mechanical Circulatory Support, Montefiore Medical Center, Albert Einstein, Bronx, NY
*Purpose: We investigated changes in cardiac wall thickness of donor hearts over time, including the peri-operative OHT period (within 4 days after transplantation) and up…
2020 American Transplant Congress
Monitoring the Removal of Donation Service Area from Lung Allocation
R. R. Goff¹, R. Daly², E. D. Lease³
¹Research, United Network for Organ Sharing, Richmond, VA, ²Mayo Clinic, Rochester, MN, ³University of Washington, Seattle, WA
*Purpose: In 2017 the Organ Procurement and Transplantation Network (OPTN) altered US lung allocation policy by replacing the donor service area (DSA) with a 250…
2020 American Transplant Congress
Comparison of Stanford Integrated Psychosocial Assessment for Transplantation Scores to Medication Adherence Assessment Findings in Kidney Transplant Candidates Undergoing Living Donor Transplant
J. Trofe-Clark¹, G. Malat¹, M. Norris¹, M. Bleicher², E. Smith³, D. Sawinski², R. Weinrieb⁴, R. Bloom²
¹Pharmacy, Hospital of Univ of Pennsylvania, Philadelphia, PA, ²Renal Division, Univ of Pennsylvania, Philadelphia, PA, ³Social Work, Hosp of Univ of Pennsylvania, Philadelphia, PA, ⁴Pyschiatry, Univ of Pennsylvania, Philadelphia, PA
*Purpose: The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) is a standardized, evaluation tool intended to assess psychosocial health in organ transplant candidates. The purpose…
2020 American Transplant Congress
The Negative Impact of Inherent Oxidative Stress in Marginal Lungs on Ex Vivo Lung Perfusion
K. Noda¹, B. J. Philips¹, M. Velayutham², T. Harano¹, P. Reck dos Santos¹, S. Shiva², P. G. Sanchez¹
¹Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh, Pittsburgh, PA
*Purpose: Identifying good quality grafts within the donor pool, ex vivo lung perfusion (EVLP) opens another window to evaluate grafts initially declined with marginal quality…
2020 American Transplant Congress
A Large Animal Model of Ex-Vivo Lung Perfusion as a Platform to Deliver Therapeutic Agents to Lungs Before Lung Transplant
T. M. Egan¹, B. Haithcock¹, M. H. Ali¹, J. W. Blackwell¹, B. Masuodi¹, S. Shipley², T. Long³, A. Akerman¹, S. Montgomery⁴, H. Yuan⁵, P. Stewart⁶, J. Potenziano⁷, C. Sekaran⁷, R. Fitch⁷
¹Surgery, UNC at Chapel Hill, Chapel Hill, NC, ²Department of Pathology and Laboratory Medicine, UNC at Chapel Hill, Chapel Hill, NC, ³Pathology and Laboratory Medicine,, UNC at Chapel Hill, Chapel Hill, NC, ⁴Pathology and Laboratory Medicine, UNC at Chapel Hill, Chapel Hill, NC, ⁵Radiology, UNC at Chapel Hill, Chapel Hill, NC, ⁶Gillings Global School of Public Health, UNC at Chapel Hill, Chapel Hill, NC, ⁷Mallinckrodt Pharmaceuticals, Hazelwood, MO
*Purpose: Ex-vivo lung perfusion (EVLP) has been used to evaluate lung function before lung transplant (LT). We used EVLP to expose lungs recovered 6 hours…